Back to search results

A Study of Pasritamig for Metastatic Castration-Resistant Prostate Cancer

This study is testing a drug called Pasritamig (given through an IV) against a placebo (an inactive IV treatment) for men with metastatic castration-resistant prostate cancer (mCRPC). This is prostate cancer that has spread and is no longer responding to hormone therapies. You might be able to join if you are an adult male with this type of prostate cancer that has spread to your bones or lymph nodes. The main goal is to see if Pasritamig helps people live longer compared to the placebo. Both groups will also receive Best Supportive Care (BSC), which is care to help with symptoms and quality of life. The study plans to include 663 participants, but its current recruitment status is unclear.

Study design
This interventional study is comparing Pasritamig to a placebo in 663 planned participants. Both treatments are given through IV infusion.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for Overall Survival (how long they live) for up to 2 years and 8 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07164443

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Recruiting
PHASE3Ages 18+InterventionalTreatment
Janssen Research & Development, LLC
~1,203 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:PasritamigPlaceboBest Supportive Care (BSC)JNJ-87189401

At a glance

Recruiting sites
171 of 173 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival (OS)
Measured over Up to 2 years and 8 months

Conditions

Metastatic Castration-resistant Prostatic Neoplasms

Explore related trials

Prostate Carcinoma

Where it's being run

173 sites across 42 states
China15
Japan12
France11
Germany11
Belgium9
Italy8
Netherlands8
South Korea7

Study leadership

  • Janssen Research & Development, LLC Clinical Trial · STUDY_DIRECTOR · Janssen Research & Development, LLC

Who to contact

Study Contact
[email protected]
844-434-4210
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed adenocarcinoma of the prostate
Metastatic castration-resistant prostate cancer (mCRPC): Disease that is metastatic either to bone, any lymph node, or both without clear evidence of other metastatic sites at the time of screening by conventional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) (chest, abdomen, and pelvis) and 99m\^Tc bone scan. Visceral disease is not allowed
PSA greater than or equal to (≥) 2 nanogram per milliliter (ng/mL) at screening
In the opinion of the investigator, the next best treatment option is a clinical trial
Participants are required to have had all life-prolonging therapies for which they are clinically eligible in the opinion of the investigator and to which they have access. Prior therapies could have been given in any disease setting (not limited to mCRPC). In particular, prior treatment specifications include receipt of the following:
Prior orchiectomy or medical castration (receiving ongoing ADT with a GnRH analog \[agonist or antagonist\]) prior to the first dose of study treatment and must continue this therapy throughout the treatment phase
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Participants are eligible if they have the following values:

Exclusion

Venous thromboembolic events within 1 month prior to the first dose of study treatment; uncomplicated (Grade ≤ 2) deep vein thrombosis is not exclusionary
Active autoimmune disease within the past 12 months that requires systemic immunosuppressive medications (eg, chronic corticosteroid, methotrexate, or tacrolimus)
Participants with Grade 1 or higher fever (≥38ºC) or active infection requiring systemic treatment within 7 days prior to randomization are ineligible. Participants must be afebrile (\<38ºC) at the time of study treatment dosing unless approved by medical monitor
Clinically significant pulmonary compromise, particularly a requirement for supplemental oxygen use (\>2 liters per minute (L/min) by nasal cannula) to maintain adequate oxygenation
Prior or concurrent second malignancy (other than the disease under study) for which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)
Any of the following within 6 months prior to first dose of study treatment:

What this trial measures

  • Overall Survival (OS)Up to 2 years and 8 months

    OS is defined as the time from randomization to date of death due to any cause.